Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex.
暂无分享,去创建一个
E. Jaffee | D. Margulies | D. Pardoll | T. Fahmy | J. Slansky | L. Boyd | J. Schneck | L F Boyd | J E Slansky | F. Rattis | D M Pardoll | D H Margulies | F M Rattis | T Fahmy | E M Jaffee | J P Schneck | Elizabeth M. Jaffee | Drew M. Pardoll | Tarek M. Fahmy | Jill E. Slansky | Frederique Rattis
[1] T. Greten,et al. Monitoring antigen-specific T cells using MHC-Ig dimers. , 2001, Current protocols in immunology.
[2] E. Margoliash,et al. T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes , 1979, The Journal of experimental medicine.
[3] D. Margulies,et al. A three-domain T cell receptor is biologically active and specifically stains cell surface MHC/peptide complexes. , 1997, Journal of immunology.
[4] S. Rosenberg,et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.
[5] M. Shields,et al. Characterization of the interactions between MHC class I subunits: a systematic approach for the engineering of higher affinity variants of beta 2-microglobulin. , 1998, Journal of immunology.
[6] A Sette,et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.
[7] T. Boon,et al. Structure of the gene of tum− transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells , 1989, Cell.
[8] S. Kozlowski,et al. Naive alloreactive CD8 T cells are activated by purified major histocompatibility complex class I and antigenic peptide , 1997, European journal of immunology.
[9] W. Gillanders,et al. Definition of TCR recognition sites on Ld-tum- complexes. , 1994, International immunology.
[10] D. Margulies,et al. Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. , 1995, Journal of immunology.
[11] Yutaka Kawakami,et al. Human tumor antigens recognized by T-cells , 1997, Immunologic research.
[12] J. Sacchettini,et al. Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Jameson,et al. T-cell-receptor affinity and thymocyte positive selection , 1996, Nature.
[14] Methods : A Companion to Methods in Enzymology , 2022 .
[15] J. Altman,et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.
[16] M. Davis,et al. A kinetic basis for T cell receptor repertoire selection during an immune response. , 1999, Immunity.
[17] A. George,et al. A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[18] L. Zitvogel,et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.
[19] Willett W. Breast. This work was supported in part by a Faculty Research Award (to B. E. H.) from the American Cancer Society and an unrestricted grant from Dupontâ€"Merck Pharmaceutical Co. (Billerica, MA). , 1997 .
[20] D. Margulies,et al. Studying interactions involving the T-cell antigen receptor by surface plasmon resonance. , 1996, Current opinion in immunology.
[21] Jonathan J. Lewis,et al. Heteroclitic Immunization Induces Tumor Immunity , 1998, The Journal of experimental medicine.
[22] P. Marrack,et al. The Bacterial and Mouse Mammary Tumor Virus Superantigens; Two Different Families of Proteins with the Same Functions , 1993, Immunological reviews.
[23] D. Margulies,et al. Solution binding of an antigenic peptide to a major histocompatibility complex class I molecule and the role of beta 2-microglobulin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[24] Philip J. R. Goulder,et al. Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.
[25] B. Moss,et al. gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.
[26] J. Berzofsky,et al. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. , 1993, Journal of immunology.
[27] D. Margulies,et al. Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120. , 1998, Journal of molecular biology.
[28] U. Utz,et al. Analysis of the Expression of Peptide–Major Histocompatibility Complexes Using High Affinity Soluble Divalent T Cell Receptors , 1997, The Journal of experimental medicine.
[29] E. Padlan,et al. Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex , 1992, The Journal of experimental medicine.
[30] Z Reich,et al. Ligand recognition by alpha beta T cell receptors. , 1998, Annual review of immunology.
[31] Mark M. Davis,et al. LIGAND RECOGNITION BY T CELL RECEPTORS , 1998 .
[32] P. Robbins,et al. Human tumor antigens recognized by T cells. , 1996, Current opinion in immunology.
[33] Mario Roederer,et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.
[34] K. Parker,et al. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.
[35] S. H. van der Burg,et al. Analogues of CTL epitopes with improved MHC class‐I binding capacity elicit anti‐melanoma CTL recognizing the wild‐type epitope , 1997, International journal of cancer.
[36] E. Jaffee,et al. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] P. Coulie,et al. Tumor antigens recognized by T cells. , 1997, Immunology today.
[38] D. Marguet,et al. Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. , 1999, Cellular immunology.
[39] D. Margulies,et al. Measuring interactions of MHC class I molecules using surface plasmon resonance. , 1995, Journal of immunological methods.
[40] F. Jotereau,et al. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions , 1996, The Journal of experimental medicine.
[41] J. Sacchettini,et al. The three-dimensional structure of an H-2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[42] D. Cheresh,et al. Human tumor antigens. , 1987, Advances in immunology.
[43] P. A. Peterson,et al. Structural basis of 2C TCR allorecognition of H-2Ld peptide complexes. , 1998, Immunity.
[44] J. H. Parish. ISOLATION AND FRACTIONATION OF RNA , 1972 .
[45] J. Renauld,et al. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. , 1997, Methods.
[46] T. Corbett,et al. A colon tumor model for anticancer agent evaluation , 1975, Cancer.
[47] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[48] D. Margulies,et al. Direct detection of major histocompatibility complex class I binding to antigenic peptides using surface plasmon resonance. Peptide immobilization and characterization of binding specificity. , 1993, The Journal of biological chemistry.
[49] T. Ezaki,et al. Isolation of dendritic cells in the rat liver lymph. , 1995, Transplantation.
[50] D. Margulies,et al. MHC Class I/peptide interactions: Binding specificity and kinetics , 1993, Journal of molecular recognition : JMR.
[51] D. Tuveson,et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[52] D. R. Lee,et al. Studies of tum- peptide analogs define an alternative anchor that can be utilized by Ld ligands lacking the consensus P2 anchor. , 1996, Journal of immunology.
[53] D. Margulies,et al. Determinant selection of major histocompatibility complex class I- restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues , 1994, The Journal of experimental medicine.
[54] L. Chen. Mimotopes of cytolytic T lymphocytes in cancer immunotherapy. , 1999, Current opinion in immunology.
[55] D. Kranz,et al. Binding energetics of T-cell receptors: correlation with immunological consequences. , 1999, Immunology today.
[56] E. Jaffee,et al. Murine tumor antigens: is it worth the search? , 1996, Current opinion in immunology.
[57] D. Speiser,et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. , 1999, International immunology.
[58] R. Henderson,et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.
[59] D. Pardoll. Therapeutic vaccination for cancer. , 2000, Clinical immunology.
[60] E. Jaffee,et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[61] D. Margulies,et al. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. , 1994, Science.
[62] E. Gilboa. The makings of a tumor rejection antigen. , 1999, Immunity.
[63] E. Coligan. Current protocols in immunology , 1991 .
[64] Tumor antigens. , 1981, The New England journal of medicine.
[65] D. Hafler,et al. Functional three-domain single-chain T-cell receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[66] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[67] D. Pardoll,et al. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. , 1998, Journal of immunology.